Article Text

Download PDFPDF
Republished: Severe hyperthermia due to oral baclofen withdrawal
  1. Vishesh Paul1,
  2. Kari Righter2,
  3. Elise Kim2,
  4. Weston Nadherny3
  1. 1 Pulmonary & Critical Care Medicine, Carle Foundation Hospital, Urbana, Illinois, USA
  2. 2 Pharmacology, Carle Foundation Hospital, Urbana, Illinois, USA
  3. 3 Internal Medicine, Carle Foundation Hospital, Urbana, Illinois, USA
  1. Correspondence to Dr Vishesh Paul; visheshpaul{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In conjunction with BMJ Case Reports, DTB will feature occasional drug-related cases that are likely to be of interest to readers. These will include cases that involve recently marketed drugs for which there is limited knowledge of adverse effects and cases that highlight unusual reactions to drugs that have been marketed for several years.


We report a case of a 53-year-old woman who presented initially with sepsis and later in her stay developed a severe and rapidly progressing hyperthermia after a decrease in oral baclofen dosage. Her fever peaked at 42.5C (108.5F), creating a broad differential diagnosis and complicating her initial sepsis diagnosis. When the oral baclofen dose was increased, the fevers resolved which confirmed the clinical diagnosis of baclofen withdrawal. Dose reductions of oral baclofen should be made gradually and with caution, and patients should be monitored for fevers as a possible symptom of baclofen withdrawal.


Baclofen, a centrally acting gamma-aminobutyric acid (GABA) derivative, reduces endogenous neurotransmitter release by binding to the GABA (b) receptors at the presynaptic terminals.1 Its clinical effect is the prevention of hyperreflexia, involuntary muscle movement and decreased muscle tone.2 Hence, baclofen is one of the most frequently used agents to control the spasticity in spinal cord injury.1 Oral baclofen does not readily cross the blood-brain barrier, which is why its benefits in spinal cord injury are typically attained through high oral doses averaging from 60 mg/day to 300 mg/day, or through intrathecal administration where it is directed at the site of action.3–5

Withdrawal of intrathecal baclofen is a well-documented medical emergency. Oral baclofen withdrawal can also lead to significant side effects such as agitation, delirium, altered mental status, dyskinesia, tachycardia and seizures.6 Few case reports link oral baclofen to high fevers and autonomic dysfunction.5–7 We …

View Full Text


  • Twitter @visheshpaul83

  • Contributors KR: wrote the initial manuscript. VP: edited the manuscript and took care of the patient. EK: took care of the patient and edited the manuscript. WN: took care of the patient and edited the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.